Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's lead stem cell platform technology, Progenza, in the U.S.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, Today received a non-refundable milestone payment of 100,000,000 JPY (approx. A$1.6M) from Kyocera Corporation (TYO:6971) as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has entered into agreements for the refinancing of the convertible notes currently on issue through an assignment and variation arrangement.
Bluechiip Limited (ASX:BCT), a leader in the development of sample tracking technology for harsh environments, provides this update to the Australian Securities Exchange.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has signed a non-binding MOU with Kyocera Corporation (Kyocera, TYO:6971).
The Directors present their report together with the financial statements, on the consolidated entity (referred to hereafter as 'the Group'), consisting of Cann Global Limited ('the Company') and the entities it controlled at the end of or during the half-year ended 31 December 2019.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its Half-Year Financial Results and Appendix 4D for the period ended 31 December 2019 (H1 FY20).
